|
US4410545A
(en)
*
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4621100A
(en)
*
|
1981-09-25 |
1986-11-04 |
The Upjohn Company |
Treatment of osteoporosis with prostaglandins
|
|
JPS5931711A
(ja)
*
|
1982-07-19 |
1984-02-20 |
シンテツクス（ユ−・エス・エイ）インコ−ポレ−テツド |
酸単離ゼラチンにより被包したｐｇｅ型組成物
|
|
US4792617A
(en)
*
|
1984-07-31 |
1988-12-20 |
Syntex (U.S.A.) Inc. |
11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienioc acid derivatives
|
|
DK606185A
(da)
*
|
1984-12-24 |
1986-06-25 |
Syntex Inc |
Prostaglandinderivater
|
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US4954346A
(en)
*
|
1988-06-08 |
1990-09-04 |
Ciba-Geigy Corporation |
Orally administrable nifedipine solution in a solid light resistant dosage form
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5595563A
(en)
*
|
1995-09-05 |
1997-01-21 |
Moisdon; Roger G. F. |
Method and apparatus for maintaining the position of body parts
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
JP3455233B2
(ja)
|
1997-04-28 |
2003-10-14 |
テキサス・バイオテクノロジー・コーポレイシヨン |
エンドテリン介在障害治療用のスルホンアミド類
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
US7169410B1
(en)
*
|
1998-05-19 |
2007-01-30 |
Sdg, Inc. |
Targeted liposomal drug delivery system
|
|
US6677473B1
(en)
|
1999-11-19 |
2004-01-13 |
Corvas International Inc |
Plasminogen activator inhibitor antagonists
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
US7897140B2
(en)
*
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
US7166719B2
(en)
|
2002-06-27 |
2007-01-23 |
Health Research, Inc. |
Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
|
|
US20050065118A1
(en)
*
|
2001-10-16 |
2005-03-24 |
Jing Wang |
Organosulfur inhibitors of tyrosine phosphatases
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
ES2367539T3
(es)
*
|
2001-12-21 |
2011-11-04 |
X-Ceptor Therapeutics, Inc. |
Moduladores heterocíclicos de receptores nucleares.
|
|
EP1465869B1
(en)
|
2001-12-21 |
2013-05-15 |
Exelixis Patent Company LLC |
Modulators of lxr
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
AU2003249742A1
(en)
*
|
2002-07-02 |
2004-01-23 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
NZ542873A
(en)
|
2003-03-05 |
2008-07-31 |
Halozyme Inc |
Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
|
|
WO2004110350A2
(en)
*
|
2003-05-14 |
2004-12-23 |
Torreypines Therapeutics, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
|
US7652044B2
(en)
*
|
2003-06-03 |
2010-01-26 |
Novartis A.G. |
P-38 inhibitors
|
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
|
EP1911754B1
(en)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
US20050203184A1
(en)
|
2003-09-10 |
2005-09-15 |
Petasis Nicos A. |
Benzo lipoxin analogues
|
|
WO2005033093A1
(en)
|
2003-09-19 |
2005-04-14 |
Galileo Pharmaceuticals, Inc. |
7,8-bicycloalkyl-chroman derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
US8519158B2
(en)
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
WO2005113523A1
(en)
|
2004-05-20 |
2005-12-01 |
Foldrx Pharmaceuticals, Inc. |
2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
|
|
WO2006009876A2
(en)
*
|
2004-06-17 |
2006-01-26 |
Cengent Therapeutics, Inc. |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
WO2006017124A2
(en)
*
|
2004-07-09 |
2006-02-16 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
CA2573644A1
(en)
|
2004-07-12 |
2006-02-16 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
|
WO2006028970A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
CA2580767A1
(en)
|
2004-09-17 |
2006-03-30 |
Whitehead Institute For Biomedical Research |
Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
|
|
ES2401285T3
(es)
|
2004-12-16 |
2013-04-18 |
The Regents Of The University Of California |
Fármacos con el pulmón como diana
|
|
JP2008524331A
(ja)
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
|
ATE534652T1
(de)
|
2005-04-01 |
2011-12-15 |
Univ California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
CA2621365C
(en)
|
2005-05-23 |
2012-09-04 |
Natural Alternatives International |
Compositions and methods for the sustained release of beta-alanine
|
|
BRPI0609191B8
(pt)
*
|
2005-06-17 |
2021-05-25 |
Ligand Pharm Inc |
métodos e compostos moduladores de receptor de androgênio
|
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
CA2645376C
(en)
|
2006-03-13 |
2017-06-20 |
Activx Biosciences, Inc. |
Aminoquinolones as gsk-3 inhibitors
|
|
CA2644784A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Jinling Chen |
Formulations of sitaxsentan sodium
|
|
JP2009530284A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
拡張期心不全を治療するための方法と組成物
|
|
US20100273776A1
(en)
*
|
2006-03-29 |
2010-10-28 |
FOLDRx PHARMACEUTICALS, INC |
Inhibition of alpha-synuclein toxicity
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
AU2007290570C1
(en)
|
2006-08-28 |
2013-08-15 |
Kyowa Kirin Co., Ltd. |
Antagonistic human LIGHT-specific human monoclonal antibodies
|
|
PL2066662T3
(pl)
|
2006-09-21 |
2013-05-31 |
Kyorin Seiyaku Kk |
Inhibitory hydrolaz serynowych
|
|
EP2223925A1
(en)
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
CA2666138A1
(en)
|
2006-10-09 |
2008-05-08 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP2617423A1
(en)
|
2006-10-19 |
2013-07-24 |
Genzyme Corporation |
Purine derivatives for the treatment of cystic diseases
|
|
CA2666149A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
|
EP2089359A2
(en)
|
2006-10-31 |
2009-08-19 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
US20080188528A1
(en)
*
|
2006-12-22 |
2008-08-07 |
Biediger Ronald J |
Modulators of C3a receptor and methods of use thereof
|
|
JP2010520200A
(ja)
|
2007-02-28 |
2010-06-10 |
クオナトウス ファーマシューティカルズ，インコーポレイテッド |
特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
SI2125698T1
(sl)
|
2007-03-15 |
2016-12-30 |
Auspex Pharmaceuticals, Inc. |
Devterirani d9-venlafaksin
|
|
MX2010000465A
(es)
*
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
|
|
CN102351880B
(zh)
*
|
2007-09-11 |
2014-11-12 |
杏林制药株式会社 |
作为gsk-3 抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
|
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
|
EP2205241B1
(en)
|
2007-09-25 |
2014-05-21 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
EP2596795A1
(en)
|
2007-11-08 |
2013-05-29 |
Ambit Biosciences Corporation |
Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
|
|
CN101917845A
(zh)
|
2007-11-21 |
2010-12-15 |
法马克西斯制药公司 |
Ssao/vap-1的卤代烯丙胺抑制剂及其用途
|
|
EP2222636B1
(en)
|
2007-12-21 |
2013-04-10 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
EP3147281A1
(en)
|
2008-03-17 |
2017-03-29 |
Ambit Biosciences Corporation |
Quinazoline derivatives as raf kinase modulators and methods of use thereof
|
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
CN102083466A
(zh)
*
|
2008-05-20 |
2011-06-01 |
科莱尼斯医疗公司 |
用于组合疗法的烟酸和nsaid
|
|
WO2010008847A2
(en)
|
2008-06-24 |
2010-01-21 |
Takeda Pharmaceutical Company Limited |
Pi3k/m tor inhibitors
|
|
EP2318035B1
(en)
|
2008-07-01 |
2019-06-12 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
|
CA2747611C
(en)
|
2009-01-06 |
2019-09-17 |
Curemark Llc |
Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
|
|
WO2010080835A1
(en)
|
2009-01-06 |
2010-07-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention oral infections by e. coli
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
MY159327A
(en)
|
2009-02-27 |
2016-12-25 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
|
CA2755976C
(en)
|
2009-03-23 |
2020-04-07 |
Ambit Biosciences Corporation |
Methods of treatment using combination therapy
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
TW201038567A
(en)
|
2009-03-27 |
2010-11-01 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
WO2010111626A2
(en)
|
2009-03-27 |
2010-09-30 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
RU2539591C2
(ru)
|
2009-04-22 |
2015-01-20 |
Аксикин Фармасьютикалз, Инк. |
Антагонисты арилсульфонамида ccr3
|
|
ES2556235T3
(es)
|
2009-04-22 |
2016-01-14 |
Axikin Pharmaceuticals, Inc. |
Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
|
|
MX2011011080A
(es)
|
2009-04-22 |
2012-02-23 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
|
|
SMT202000092T1
(it)
|
2009-05-14 |
2020-05-08 |
Ambit Biosciences Corp |
Formulazione essiccata a spruzzo o liofilizzata di ac220
|
|
CA2767008C
(en)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
AU2010270605B2
(en)
|
2009-07-08 |
2014-07-31 |
Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP2459561A1
(en)
|
2009-07-30 |
2012-06-06 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
|
CN102724978A
(zh)
|
2009-08-14 |
2012-10-10 |
塞伦尼斯治疗公司 |
用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
TW201120037A
(en)
*
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011057214A2
(en)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
MX2012006877A
(es)
|
2009-12-18 |
2012-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
|
|
IN2012DN04858A
(ja)
*
|
2009-12-23 |
2015-09-25 |
Map Pharmaceuticals Inc |
|
|
CN102791701B
(zh)
|
2009-12-30 |
2014-02-12 |
深圳信立泰药业股份有限公司 |
作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
|
|
PL2531501T3
(pl)
|
2010-02-03 |
2014-05-30 |
Takeda Pharmaceuticals Co |
Inhibitory kinazy 1 regulującej sygnał apoptotyczny
|
|
EP2542542B1
(en)
|
2010-03-02 |
2015-04-22 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
TW201134820A
(en)
|
2010-03-17 |
2011-10-16 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide CCR3 antagonists
|
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
|
EP2576513A1
(en)
|
2010-06-01 |
2013-04-10 |
Biotheryx Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
|
AU2011261501B2
(en)
|
2010-06-01 |
2016-01-21 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
|
|
JP5855095B2
(ja)
|
2010-06-07 |
2016-02-09 |
ノボメディックス, エルエルシーNovomedix, Llc |
フラニル化合物およびその使用
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
WO2012012370A1
(en)
|
2010-07-19 |
2012-01-26 |
Summa Health System |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
WO2012030948A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
AU2011296078B2
(en)
|
2010-09-01 |
2015-06-18 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
EP2611812A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
EP2663553B1
(en)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
EP2611793A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
EP2611448A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
AU2011296046B2
(en)
|
2010-09-01 |
2015-05-14 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
|
US8859502B2
(en)
|
2010-09-13 |
2014-10-14 |
Celgene Corporation |
Therapy for MLL-rearranged leukemia
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
US20120088769A1
(en)
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Ｍｅｉ製藥公司 |
（α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
|
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
JP5976100B2
(ja)
|
2011-04-21 |
2016-08-23 |
キュアマーク リミテッド ライアビリティ カンパニー |
神経精神障害の処置のための化合物
|
|
KR20140042868A
(ko)
|
2011-06-23 |
2014-04-07 |
맵 파마슈티컬스, 인코포레이티드 |
신규한 플루오로에르골린 유사체
|
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
|
MX358254B
(es)
|
2011-09-02 |
2018-08-10 |
Syndax Pharmaceuticals Inc |
Métodos para el tratamiento de cáncer de mama.
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
CA2849708A1
(en)
|
2011-09-23 |
2013-03-28 |
Celgene Corporation |
Romidepsin and 5 - azacitidine for use in treating lymphoma
|
|
CA2849903A1
(en)
|
2011-09-26 |
2013-04-04 |
Celgene Corporation |
Combination therapy for chemoresistant cancers
|
|
TW201700103A
(zh)
|
2011-11-01 |
2017-01-01 |
西建公司 |
利用胞嘧啶核苷類似物之口服配方治療癌症的方法
|
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
|
CA2859175A1
(en)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
PT2822936T
(pt)
|
2012-03-07 |
2021-12-02 |
Univ Of Delhi |
Derivados da aminoquinolina e suas utilizações
|
|
WO2013138617A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
WO2013148919A1
(en)
|
2012-03-30 |
2013-10-03 |
The Regents Of The University Of Colorado, A Body Corporate |
Treatment of multiple myeloma
|
|
AU2013255103B2
(en)
|
2012-05-02 |
2016-09-29 |
Syntara Limited |
Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US8551535B1
(en)
|
2012-08-06 |
2013-10-08 |
Sarah McCann |
Homeopathic remedies and methods for enhancing weight loss
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
WO2014039748A1
(en)
|
2012-09-07 |
2014-03-13 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
|
AU2013202506B2
(en)
|
2012-09-07 |
2015-06-18 |
Celgene Corporation |
Resistance biomarkers for hdac inhibitors
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
WO2014074765A2
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
AU2013202507B9
(en)
|
2012-11-14 |
2015-08-13 |
Celgene Corporation |
Inhibition of drug resistant cancer cells
|
|
WO2014085633A1
(en)
|
2012-11-30 |
2014-06-05 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
|
CA2895829A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
|
AU2014205324A1
(en)
|
2013-01-11 |
2015-07-30 |
Mayo Foundation For Medical Education And Research |
Vitamins C and K for treating polycystic diseases
|
|
HK1219654A1
(zh)
|
2013-02-22 |
2017-04-13 |
University Of Southern California |
用於治疗眼科疾病和病症的方法
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
EP3935944A1
(en)
|
2013-03-15 |
2022-01-12 |
University Of Southern California, USC Stevens |
Compounds for the treatment of musculoskeletal diseases
|
|
SG10201800188SA
(en)
|
2013-03-15 |
2018-02-27 |
Univ California |
Acyclic nucleoside phosphonate diesters
|
|
WO2014160698A1
(en)
|
2013-03-26 |
2014-10-02 |
Celgene Corporation |
SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
SG11201509982UA
(ja)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
EP3083589B1
(en)
|
2013-12-20 |
2019-12-18 |
Sunshine Lake Pharma Co., Ltd. |
Substituted piperazine compounds and methods of use thereof
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
JP6568926B2
(ja)
|
2014-03-20 |
2019-08-28 |
カペラ セラピューティクス，インコーポレーテッド |
癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
|
|
CA2943220C
(en)
|
2014-03-20 |
2024-01-16 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
WO2015148867A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
JP2017515854A
(ja)
|
2014-05-12 |
2017-06-15 |
クオナトウス ファーマシューティカルズ，インコーポレイテッド |
カスパーゼ阻害剤による慢性肝疾患の合併症の治療
|
|
WO2015195786A2
(en)
|
2014-06-17 |
2015-12-23 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
WO2016025129A1
(en)
|
2014-08-14 |
2016-02-18 |
Alhamadsheh Mamoun M |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
|
CN111808136B
(zh)
|
2014-09-15 |
2024-06-11 |
加利福尼亚大学董事会 |
核苷酸类似物
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
MX381224B
(es)
|
2014-10-31 |
2025-03-12 |
Massachusetts Gen Hospital |
Potentes moduladores de gamma-secretasa.
|
|
JP6800853B2
(ja)
|
2014-12-11 |
2020-12-16 |
ピエール、ファーブル、メディカマン |
抗ｃ１０ｏｒｆ５４抗体およびその使用
|
|
TWI703133B
(zh)
|
2014-12-23 |
2020-09-01 |
美商艾克斯基製藥公司 |
３,５-二胺基吡唑激酶抑制劑
|
|
MX2017009405A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo ergolina y usos de estos.
|
|
EP3247357A4
(en)
|
2015-01-20 |
2018-07-11 |
Xoc Pharmaceuticals, Inc |
Isoergoline compounds and uses thereof
|
|
KR20250005465A
(ko)
|
2015-03-03 |
2025-01-09 |
키맵 리미티드 |
항체, 용도 및 방법
|
|
ES2986548T3
(es)
|
2015-03-20 |
2024-11-11 |
Syndax Pharmaceuticals Inc |
Combinación de inhibidor de HDAC y anticuerpo anti-PD-1 para el tratamiento del cáncer, en donde la combinación no comprende 5-azacitidina
|
|
WO2016176617A2
(en)
|
2015-04-29 |
2016-11-03 |
New York University |
Method for treating high-grade gliomas
|
|
KR20240125709A
(ko)
|
2015-06-23 |
2024-08-19 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
|
|
SMT202100712T1
(it)
|
2015-08-17 |
2022-01-10 |
Kura Oncology Inc |
Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi
|
|
BR112018003238A2
(en)
|
2015-09-02 |
2018-09-25 |
Syndax Pharmaceuticals, Inc. |
patient selection for combination therapy
|
|
JP2018527362A
(ja)
|
2015-09-11 |
2018-09-20 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． |
置換されたヘテロアリール化合物および使用方法
|
|
US20180360959A1
(en)
|
2015-09-25 |
2018-12-20 |
Universität Duisburg-Essen |
Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease
|
|
RS61645B1
(sr)
|
2015-10-30 |
2021-04-29 |
Neurocrine Biosciences Inc |
Valbenazin ditozilat i njihovi polimorfi
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CN108883103A
(zh)
|
2015-12-02 |
2018-11-23 |
阿斯特来亚治疗有限责任公司 |
哌啶基痛敏肽受体化合物
|
|
JP6869988B2
(ja)
|
2015-12-23 |
2021-05-12 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
（Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
|
|
CA3010286A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
SG11201805779TA
(en)
|
2016-01-08 |
2018-08-30 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
US10407437B2
(en)
|
2016-03-08 |
2019-09-10 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
|
EP3426301A4
(en)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
VERBUNDNANOPARTICLES AND USES THEREOF
|
|
EP3442940A1
(en)
|
2016-04-11 |
2019-02-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
EP3454904B1
(en)
|
2016-05-13 |
2022-12-14 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
|
WO2018013693A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
|
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
IL292938A
(en)
|
2016-09-19 |
2022-07-01 |
Mei Pharma Inc |
Combined treatment
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
TW201818965A
(zh)
|
2016-11-03 |
2018-06-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
|
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
TW201828932A
(zh)
|
2016-11-09 |
2018-08-16 |
美商諾沃麥迪斯有限責任公司 |
1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
|
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
EP3548007A4
(en)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
METHOD OF TREATMENT OF CANCER
|
|
WO2018102673A1
(en)
|
2016-12-02 |
2018-06-07 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
CA3051830A1
(en)
|
2017-01-27 |
2018-08-02 |
Neurocrine Bioscienes, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
EP3576755A4
(en)
|
2017-02-02 |
2020-12-02 |
McMaster University |
BICARBONATE AS A POTENTIALIZER OF ANTIMICROBIAL AGENTS
|
|
CN116730920A
(zh)
|
2017-02-17 |
2023-09-12 |
文涵治疗有限公司 |
Ag-10的制备方法、其中间体及其盐
|
|
TWI738314B
(zh)
|
2017-02-21 |
2021-09-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
EP3601235B1
(en)
|
2017-03-30 |
2026-03-04 |
XWPharma Ltd. |
Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
|
|
US12226464B2
(en)
|
2017-04-10 |
2025-02-18 |
Curemark, Llc |
Compositions for treating addiction
|
|
US11583570B2
(en)
|
2017-04-24 |
2023-02-21 |
Tsinghua University |
Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
WO2018223065A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
WO2019002228A1
(en)
|
2017-06-26 |
2019-01-03 |
Institut Pasteur |
TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
|
|
MX2020001207A
(es)
|
2017-08-07 |
2020-03-20 |
Kura Oncology Inc |
Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019033330A1
(en)
|
2017-08-17 |
2019-02-21 |
Xw Laboratories, Inc. |
PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
|
|
AU2018324070B2
(en)
|
2017-09-01 |
2023-05-18 |
East Carolina University |
Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
|
|
EP3679051B1
(en)
|
2017-09-04 |
2021-12-29 |
XWPharma Ltd. |
Preparation and use of reactive oxygen species scavenger
|
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
CN111356461A
(zh)
|
2017-10-04 |
2020-06-30 |
加利福尼亚大学董事会 |
免疫调节性低聚糖
|
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
US20190216751A1
(en)
|
2017-11-15 |
2019-07-18 |
California State University Northridge |
Compositions and Methods for the Treatment and Prevention of Cancer
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
TW202406538A
(zh)
|
2018-01-10 |
2024-02-16 |
美商克拉治療有限責任公司 |
包含苯基磺醯胺之醫藥組合物及其治療應用
|
|
PL3737665T3
(pl)
|
2018-01-10 |
2026-04-20 |
XWPharma Ltd. |
Proleki ketaminy, ich kompozycje i zastosowania
|
|
TWI817999B
(zh)
|
2018-03-23 |
2023-10-11 |
美商文涵治療有限公司 |
使用ag10治療ttr澱粉樣沉積症之方法
|
|
EP4643950A3
(en)
|
2018-04-27 |
2026-01-14 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
|
KR20250115460A
(ko)
|
2018-05-07 |
2025-07-30 |
신닥스 파마슈티컬스, 인크. |
병용 요법을 위한 환자의 선정
|
|
WO2019232724A1
(en)
|
2018-06-06 |
2019-12-12 |
Xw Laboratories, Inc. |
Compounds as nuclear transport modulators and uses thereof
|
|
AU2019287524A1
(en)
|
2018-06-14 |
2020-12-24 |
Neurocrine Biosciences, Inc. |
VMAT2 inhibitor compounds, compositions, and methods relating thereto
|
|
EP3814327A1
(en)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
|
WO2020019247A1
(en)
|
2018-07-26 |
2020-01-30 |
Xw Laboratories, Inc. |
Compounds as neurokinin-1 receptor antagonists and uses thereof
|
|
EP3829640A4
(en)
|
2018-08-01 |
2022-05-25 |
McMaster University |
Methods for inhibiting microbe growth
|
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
SI3836920T1
(sl)
|
2018-08-17 |
2026-02-27 |
Eidos Therapeutics, Inc. |
Formulacije AG10
|
|
CN114042070A
(zh)
|
2018-09-30 |
2022-02-15 |
凯瑞康宁生物工程（武汉）有限公司 |
作为神经元组胺受体-3拮抗剂的化合物及其用途
|
|
EP3873469A2
(en)
|
2018-11-01 |
2021-09-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US12391705B2
(en)
|
2018-12-19 |
2025-08-19 |
Shy Therapeutics, Llc |
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
TW202038953A
(zh)
|
2018-12-21 |
2020-11-01 |
美商庫拉腫瘤技術股份有限公司 |
鱗狀細胞癌之治療
|
|
CN113874080B
(zh)
|
2019-02-06 |
2024-09-27 |
戴斯阿尔法公司 |
Il-17a调节剂及其用途
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
ES2988904T3
(es)
|
2019-03-07 |
2024-11-22 |
Nobo Medicine Inc |
Inhibidores de caspasa y métodos de utilización de los mismos
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020214834A1
(en)
|
2019-04-19 |
2020-10-22 |
Ligand Pharmaceuticals Inc. |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
WO2020236828A1
(en)
|
2019-05-20 |
2020-11-26 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
US20220249707A1
(en)
|
2019-05-20 |
2022-08-11 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
US20220274921A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
US11098002B2
(en)
|
2019-07-26 |
2021-08-24 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
EP4031534A1
(en)
|
2019-09-16 |
2022-07-27 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
EP4034236A1
(en)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Compounds useful for treating liver diseases
|
|
CA3128410A1
(en)
|
2019-10-11 |
2021-04-15 |
Waterstone Pharmaceuticals (Wuhan) Co., Ltd. |
Ws-635 uses thereof in medicine
|
|
CN114901280B
(zh)
|
2019-11-05 |
2025-05-27 |
德米拉公司 |
MrgprX2拮抗剂及其用途
|
|
WO2021092240A1
(en)
|
2019-11-05 |
2021-05-14 |
Dermira, Inc. |
Mrgprx2 antagonists for the treatment of inflammatory disorders
|
|
EP4055011A1
(en)
|
2019-11-05 |
2022-09-14 |
Dermira, Inc |
Mrgprx2 antagonists and uses thereof
|
|
CN112851622B
(zh)
|
2019-11-28 |
2023-01-10 |
中国海洋大学 |
一种大环内酯布雷菲德菌素a酯类衍生物及应用
|
|
TW202136238A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
TW202136237A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
EP4157271A1
(en)
|
2020-05-29 |
2023-04-05 |
Boulder Bioscience LLC |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2021262992A1
(en)
|
2020-06-24 |
2021-12-30 |
Neurobo Pharmaceuticals, Inc. |
Gemcabene for treatment of cytokine storms and viral-induced inflammation
|
|
WO2022002011A1
(zh)
|
2020-06-30 |
2022-01-06 |
东莞市东阳光新药研发有限公司 |
2-(取代的嘧啶基)噻唑甲酰胺化合物的盐及其组合物和用途
|
|
US12024521B2
(en)
|
2020-06-30 |
2024-07-02 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
US20240317681A1
(en)
|
2020-07-07 |
2024-09-26 |
Sunshine Lake Pharma Co., Ltd. |
Pyrrolidine amide derivative salt and use thereof
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20240025863A1
(en)
|
2020-09-16 |
2024-01-25 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2022087335A1
(en)
|
2020-10-23 |
2022-04-28 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
CN117203196A
(zh)
|
2020-12-14 |
2023-12-08 |
拜欧斯瑞克斯公司 |
Pde4降解剂、药物组合物和治疗应用
|
|
US20240058336A1
(en)
|
2020-12-16 |
2024-02-22 |
Impact Biomedicines, Inc. |
Dosing of fedratinib
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
KR20230169979A
(ko)
|
2021-03-10 |
2023-12-18 |
다이스 몰레큘스 에스브이, 인크. |
알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
|
|
JP7644257B2
(ja)
|
2021-04-09 |
2025-03-11 |
中美華世通生物医薬科技（武漢）股▲ふん▼有限公司 |
Ｗｓ６３５薬物の使用
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
WO2022266249A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2022266248A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2023044297A1
(en)
|
2021-09-14 |
2023-03-23 |
Impact Biomedicines, Inc. |
Fedratinib for treating myeloproliferative disorders
|
|
CA3236150A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
EP4441038A1
(en)
|
2021-11-30 |
2024-10-09 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
CA3253352A1
(en)
|
2022-03-02 |
2023-09-07 |
Mitopower, Inc. |
NEW PROMEDICINAL PRODUCTS DERIVED FROM NICOTINIC ACID AND RIBOSE
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
CA3255290A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
NEW GSPT1 COMPOUNDS AND METHODS FOR USING THE NEW COMPOUNDS
|
|
JP2025516555A
(ja)
|
2022-05-10 |
2025-05-30 |
バイオセリックス， インコーポレイテッド |
Ｃｄｋタンパク質分解因子、医薬組成物、及び治療応用
|
|
EP4584259A1
(en)
|
2022-09-09 |
2025-07-16 |
Innovo Therapeutics, Inc. |
Ck1alpha and dual ck1alpha / gspt1 degrading compounds
|
|
CA3268510A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions containing 3,3'-diindolmythane for treating a closed, non-bleeding head wound
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
EP4608838A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
US20240174695A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Bicyclic Heteroaryl Compounds
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
EP4626865A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2025026195A1
(zh)
|
2023-07-28 |
2025-02-06 |
广东东阳光药业股份有限公司 |
取代的含氮双环化合物及其用途
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
TW202530223A
(zh)
|
2023-09-27 |
2025-08-01 |
美商艾索司特瑞克斯公司 |
Ｍｙｓｔ抑制劑
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025201633A1
(en)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
An agent for reducing amyloid formation
|
|
WO2025231261A1
(en)
|
2024-05-01 |
2025-11-06 |
Protego Biopharma, Inc. |
Bicyclic and heterocyclic amide compounds
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|